Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

ClinicalTrials.gov ID: NCT06147830

Public ClinicalTrials.gov record NCT06147830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multinational Observational Longitudinal Study to Describe the Patient Characteristics, Health Care Interventions, and Health Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

Study identification

NCT ID
NCT06147830
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
AstraZeneca
Industry
Enrollment
2,202 participants

Conditions and interventions

Conditions

Interventions

  • None (Observational study) Other

Other

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2023
Primary completion
Nov 29, 2024
Completion
Nov 29, 2024
Last update posted
Nov 2, 2025

2023 – 2024

United States locations

U.S. sites
25
U.S. states
16
U.S. cities
25
Facility City State ZIP Site status
Research Site Chandler Arizona 85224
Research Site Orange California 92868
Research Site Sacramento California 95817
Research Site Torrance California 90509
Research Site Lakewood Colorado 80228-1527
Research Site Hartford Connecticut 06102
Research Site Orlando Florida 32803
Research Site Tampa Florida 33606
Research Site Glenview Illinois 60026
Research Site Kansas City Kansas 66160
Research Site Lexington Kentucky 40536
Research Site Royal Oak Michigan 48073
Research Site Kansas City Missouri 64111
Research Site St Louis Missouri 63110
Research Site Albany New York 12208
Research Site New Hyde Park New York 11040
Research Site Staten Island New York 10305
Research Site Stony Brook New York 11794
Research Site Valhalla New York 10595
Research Site Chapel Hill North Carolina 27514
Research Site Columbus Ohio 43210
Research Site Toledo Ohio 43614
Research Site Portland Oregon 97201-3098
Research Site Dallas Texas 75390
Research Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06147830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2025 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06147830 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →